key: cord-0912392-rp581jmg
authors: Rao, G.S.N. Koteswara; Gowthami, Buduru; Naveen, N. Raghavendra; Samudrala, Pavan Kumar
title: An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19
date: 2021-10-08
journal: Current Research in Pharmacology and Drug Discovery
DOI: 10.1016/j.crphar.2021.100063
sha: 557bed5e2842ef9887a39046d954c609af6aaeda
doc_id: 912392
cord_uid: rp581jmg

The outbreak of COVID-19 was recognized in December 2019 in China and as of October5th, the pandemic was swept through 216 countries and infected around 34,824,108 individuals, thus posing an unprecedented threat to world's health and economy. Several researchers reported that, a significant mutation in membrane proteins and receptor binding sites of preceding severe acute respiratory syndrome coronavirus (SARS-CoV) to turned as novel SARS-CoV-2 virus and disease was named as COVID-19 (Coronavirus disease 2019). Unfortunately, there is no specific treatment available for COVID-19 patients. The lessons learned from the past management of SARS-CoV and other pandemics, have provided some insights to treat COVID-19. Currently, therapies like anti-viral treatment, immunomodulatory agents, plasma transfusion and supportive intervention etc., are using to treat the COVID-19. Few of these were proven to provide significant therapeutic benefits in treating the COVID-19, however no drug is approved by the regulatory agencies. As the fatality rate is high in patients with comorbid conditions, we have also enlightened the current in-line treatment therapies and specific treatment strategies in comorbid conditions to combat the emergence of COVID-19. In addition, pharmaceutical, biological companies and research institutions across the globe have begun to develop thesafe and effective vaccine for COVID-19. Globally around 170 teams of researchers are racing to develop the COVID-19 vaccine and here we have discussed about their current status of development. Furthermore, recent patents filed in association with COVID-19 was elaborated. This can help many individuals, researchers or health workers, in applying these principles for diagnosis/prevention/management/treatment of the current pandemic.

The coronavirus, believed to be originated 800 years before from the bats, as confirmed by many researchers(Y. Chen et al., 2020; Paules et al., 2020) . On basis of genetic features, family coronaviridae is categorized as α, β, λ, and δ, where alpha (α) and beta (β) coronavirus are proven as pathogenic to humans and mammalians. Coronaviruses are a form of positive strand non segmented RNA viruses that can cause serious respiratory and neurological illness (Weiss & Leibowitz, 2011) . Six different types of coronaviruses can cause disease among the humans, two of them can cause middle east respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS-CoV), while the rest four (HKU1, 229E,NL63 and OC43) are less pathogenic will cause only common cold (Cui et al., 2019; S. Su et al., 2016) . MERS-CoV and SARS-CoV outbreak was happened in Middle east (2012) and China (2002) respectively (Zaki et al., 2012; Zhong et al., 2003) .

Again, in December 2019, few patients who are linked with seafood market in Wuhan of China, were shown pneumonia like symptoms. Consequently, about 20,000 sequences from each sample were obtained to match the genome. Genome matches confirmed 85% similarity with SARS-like β-coronavirus (N. . Further investigations on isolated virus conforms the new strain of Coronavirus and named this new virus as SARS-CoV 2 (Fig. 1) . 

As the present pandemic is of viral origin, the primary focussed repurposing of drugs is in the area of antivirals and the rapid trials are going on with antiviral drugs.

As on date, 20 clinical trials are ongoing with combination of lopinavir/ritonavir as per the statistics at clinicaltrials.gov. Among them 13trials reached phase-2 and 11 trials were reached to phase-3. The priority for these drugs is due to their efficacy against earlier viruses SARS-CoV, MERS-CoV and HIV (Lythgoe & Middleton, 2020) . Both of these drugs are protease inhibitors. Lopinavir has insufficient oral bioavailability due to the rapid catabolism by the specific enzyme, 3A4 isoenzyme which is a part of Cytochrome P450 enzyme system (Sham et al., 1998) .In order to overcome this loss and significantly enhance the halflife of lopinavir, the concomitant administration of ritonavir is followed to inhibit the enzymatic catabolism of lopinavir. The combined efficacy of lopinavir/ritonavir has been proved against SARS-CoV during 2004 (Chu et al., 2004) . However, yet no significant data is (Cao et al., 2020a) .

Few earlier studies revealed that the use of lopinavir/ritonavir combination therapy has shown reduction in viral loads, fever, and pulmonary damage (Meini et al., 2020) .

where 99 severe COVID-19 patients received lopinavir/ritonavir and 100 patients received standard care for a duration of 2 weeks. The results of this study are statistically nonsignificant between the two groups, but shown more clinical improvement with the lopinavir/ritonavir patients compared with standard care (Cao et al., 2020b; Meini et al., 2020) .

A novel nucleotide analogue, Remdesivir, having antiviral effect against Ebola, Marburg, SARS-CoV and MERS-CoV has been in clinical trials to evaluate its effect against COVID-19(Sheahan et al., 2017; Warren et al., 2016) . Remdesivir is found to have a therapeutic benefit against COVID-19 based on the recovery rate in USA in remdesivir treated patients (Holshue et al., 2020; Lythgoe & Middleton, 2020) . As on date there are 41 ongoing clinical trials to check the efficacy of remdesivir against COVID-19.

CYP3A inhibitors are potential boosters of other antivirals as well, in particular remdesivir (Shytaj et al., 2021; Xie & Wang, 2021) .

With a significant benefit of reducing the mortality of COVID-19 patients, USFDA has issued emergency use authorization for emergency use of remdesivir in COVID-19

With Moderate COVID-19, 2020; Samudrala et al., 2020) . It has been reported that treatment with remdesivir and chloroquine has shown effective response against recently emerged coronavirus (Khan et al., 2020; Samudrala et al., 2020; . However, still additional scientific data is necessary to be developed to establish the treatment strategy and dosage regimen.

However, in another study the use of remdesivir has not shown statistically significant improvement in clinical benefits, however shown reduction in recovery time of COVID patients in clinical trials and non-significant reduction in mortality rate (Davies et al., 2020;  Yeming Wang et al., 2020) . As there is no other available treatment option at this emergency situation, USFDA has re-issued the emergency use authorization for use of this drug(COVID-J o u r n a l P r e -p r o o f 9 19 Update: FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19 | FDA, 2020 ; USFDA, 2020).

Favipiravir is found effective against wide range of viruses like resistant influenza, and able to inhibit RNA viruses like arena-, bunya-and filo-viruses (Delang et al., 2018; Jiancheng Zhang et al., 2020) . Favipiravir has also shown potential benefit against SARS-CoV-2 .As a further attempt, a combination of favipiravir with interferon- and also with baloxavirmarboxil are under clinical trials (Khan et al., 2020) . tenofovir to test the efficacy of these drugs. (Lythgoe & Middleton, 2020) .

EIDD-2801 is an antiviral drug that is providing potential results against SARS-CoV-2. EIDD-2801 is comparatively more preferred than remdesivir as the former is meant for oral administration whereas the latter must rely on intravenous administration. EIDD-1931 is another analogue, that is found to be effective against several types of viruses like SARS-CoV, MERS-CoV, and even the newly emerging SARS-CoV-2 based on cell based assays (Jiancheng Zhang et al., 2020) .

Corticosteroids are known to treat acute respiratory distress disease and sepsis due to their anti-inflammatory, antifibrotic effects and suppression of collagen deposition. Use of dexamethasone for COVID-19 therapy has been proposed with the reported advantages of minimum fatality rate and hospital stays of SARS infect patients(R. C. Chen et al., 2006 Disease , 2020).

The use of corticosteroids for SARS-CoV and MERS-CoV has reported detrimental effects with increased mortality and nosocomial infections for influenza and delayed virus clearance(J. W. . Corticosteroids therapy has offered controversial implications in COVID-19. Even though there is an improvement in the symptoms and oxygenation with severe COVID-19 patients, there are also cases with increased fatality rate in observational studies. Hence, a more randomized controlled trials are to be conducted for better scientific understanding of the use of corticosteroids(J. W. .

Early COVID-19 pneumonia was reported to be managed well with low-dose and short-term use of methylprednisolone . ARDS patients has shown decreased rate of mortality in a study with the use of methylprednisolone(C. . suggesting that heparin is found to be effective in COVID-19 management beyond anticoagulant effect through its pleiotropic activity (Gozzo et al., 2020) . However,studies with large number of subjects are necessary to confirm the benefits of heparin in management of COVID-19.

.

Chloroquine is a well-known drug for treating malaria and autoimmune diseases which is also known for its broad-spectrum antiviral action. In addition to the earlier reports on effect of chloroquine against SARS-CoV(Keyaerts et al., 2004; Savarino et al., 2006; Yiwu Yan et al., 2013) , it has also been found effective against SARS-CoV-2 in improving the disease conditions like pneumonia, and pulmonary lesions . Chloroquine is known to decrease the severity and duration of disease(Jiancheng J o u r n a l P r e -p r o o f 11 .In addition to chloroquine, its analogue and a relatively low toxic agent, hydroxychloroquine has been found to be another potential outcome for dealing with SARS-CoV-2 patients(J. .

Chloroquine show antiviral effect by inhibiting the glycosylation of S-protein of angiotensin converting enzyme-2 and also by increasing the pH of acidic cellular organelles thereby avoiding the fusion of virus into the host cells (Savarino et al., 2003 (Savarino et al., , 2006 .These antimalarial agents are also shown to cause decreased expression of cytokines thereby minimizing the intensity of COVID-19 .Their low cost and high availability in addition to potency against COVID-19 has made them prominent for the treatment of COVID-19. Gautret et al. reported that a combination of hydroxychloroquine and azithromycin has shown significant reduction in viral load in COVID-19 patients (Gautret et al., 2020) .

Later reports revealed that a short term use of hydroxychloroquine is safe and also the combination of chloroquine with azithromycin could develop other side effects like cardiovascular complications, angina, chest pain and heart failure(Lane et al., 2020).

However, there are earlier reports as well as recovery trial stating that chloroquine and hydroxychloroquine were not effective against viral treatments like SARS-CoV-2 and no significant benefit over mortality rate (Group, 2020; Savarino, 2011) .

2.5.1. Tocilizumab and sarilumab COVID-19 patients are known to invoke a hyperinflammatory state with multiple calls and mediators like interleukins (IL-1, IL-6, IL-12, IL-18), tumor necrosis factor alpha (TNF) etc. Seriously ill patients infected with COVID-19 are found to have cytokine dysregulation majorly involved with IL-6. Hence, IL-6 inhibitors are proposed in the treatment strategies for COVID-19 (Cao et al., 2020b) .

COVID-19 patients with cytokine storm,particularly IL-6 are found to be responding with IL-6 receptor antagonists namely tocilizumab and sarilumab. Numerous clinicals are going on with tocilizumab and sarilumab (Mehta et al., 2020) .

Tocilizumab and sarilumab, the targeted monoclonal antibodies are found to reduce the evident features of cytokine driven hyperinflammation like dyspnoea, persistent fever and elevated markers showing improved clinical outcomes through decreased cell proliferation, differentiation, oxidative stress and exudation (Cao et al., 2020b) . These antibodies are included in the international guidelines for management of severe of critically ill patients.

J o u r n a l P r e -p r o o f 12 Numerous clinical trials are going on for increased interest in testing the clinical implications of these drugs. Tocilizumab is reported to be reducing the likelihood of advancement to death in COVID-19 patients (Salama et al., 2020) .

Bevacizumab is a recombinant humanized monoclonal antibody that was approved by USFDA for several types of cancers like metastatic colorectal cancer, lung cancer, renal cancer, cervical cancer, ovarian cancer, etc. As it acts against vascular endothelial growth factor (VEGF), bevacizumab is proposed to be used in treatment of COVID-19 because VEGF is responsible for acute respiratory distress, pulmonary edema, dyspnea, and acute lung injury. Clinical trials are initiated on this drug for confirming its application in clinical improvement of COVID-19 cases (Samudrala et al., 2020) .Bevacizumab is well known to treat acute respiratory distress syndrome which is highly associated complication in COVID-19 ill patients(Jiancheng .

In vitro studies revealed that the anti-parasitic agent, ivermectin could effectively act against SARS-CoV-2 growth in cell cultures (Caly et al., 2020) .Further studies are necessary to prove its efficacy and safety for managing SARS-CoV-2 in animals or humans. Melo et al., reported that their study supports the use of immunomodulatory drugs like ivermectin to improve the clinical condition of COVID-19 infected patients (Melo et al., 2021) .

Plasma therapy has shown improved signs of relief and treatment. Here, in this treatment convalescent plasma collected from the recovered COVID-19 patients and it has been approved by several regulatory bodies for treatment (Roback & Guarner, 2020) .

USFDA has granted clinical permission for the application of convalescent plasma to the treatment of critically ill patients affected by COVID-19(Investigational COVID-19 Convalescent Plasma-Emergency INDs Frequently Asked Questions, 2020) .Several studies reported that,recovery from the infection was observed approximately after a week of transfusion of convalescent plasma.

Vitamin C and D are found to be beneficial in controlling the disease condition of (Grant et al., 2020) .Zinc supplementation is thought to combat the loss of taste and smell symptoms in COVID-19

patients. In addition, the role of zinc as potential inhibitor of various RNA viruses such as SARS-CoV has initiated the clinical trials to test its effect against COVID-19(Keyhan et al., 2020; Jiancheng Zhang et al., 2020) .

A highly selective janus kinase (JAK) inhibitor, Baricitinib is found to be useful in the management of COVID-19 disease by impeding the hyperimmune responses and also by inhibiting the invasion of host cells with SARS-CoV-2 virus (Richardson et al., 2020 (Leng et al., 2020) .

The use of inhaled nitric oxide in SARS infected patients has shown improved arterial oxygenation and reduced the need of ventilation. Hence, clinical trials are going on for testing the application of inhaled nitric oxide in COVID-19 patients suffering with acute respiratory distress syndrome(L. Chen et al., 2004) .

Interferon alpha-1a, alpha-1b, beta-1a, beta-1b are known to show beneficial effects in 

It is reported that COVID-19 infected patients with comorbidities are at higher risk than others . (Barron et al., 2020) It is observed that major proportion of COVID-19 patients are having comorbidities and it might be giving a claim that patients suffering from diseases like diabetes, hypertension are more prone to infection by SARS-CoV-2. One of the reasons might be the over expression of angiotensin-converting enzyme 2 (ACE2)in these diseases(Gracia-Ramos, 2020).

The pathogenic viruses SARS-CoV and SARS-CoV-2 bind to the host cells through ACE-2 receptors which is expressed on different organs like lungs, kidneys, blood vessels and intestine (Wan et al., 2020) . Patients (Type-1, type-2 diabetes, and hypertension patients)

taking ACE inhibitors and angiotensin II type-I receptor blockers (ARBs) are known to show upregulation of ACE2(X. C. Li et al., 2017) . Thiazolidinediones and ibuprofen usage are also meant for over expression of ACE2.

These factors, in turn favour the infection of coronavirus in humans due to the overexpression of ACE2. However, this hypothesis may need strong scientific assessment with more clinical investigation. In addition, there is a conflict with ACE2 pharmacological effects and its polymorphic effects. COVID-19 patients treated with medicaments that increase ACE2 levels are at still higher risk due to comorbidities like diabetes, hypertension, and cardiac diseases .However, the prevalence of comorbid diseases varies from country to country based on the age factors and living styles. Since non-steroidal anti-inflammatory drugs are commonly used in elderly patients, this may result in worsening of the condition of COVID-19 patients with adverse effects like renal failure, heart problems, and gastrointestinal toxicity. Hence, a proper management of the treatment should be done (Wongrakpanich et al., 2018) .Overall, the severity of the diseaseis high in older population and the population who had more significant number of comorbid conditions than others. These results may suggest that age and comorbidities are risk factors for COVID-19(J. .

16 Diabetes is one of the most prevalent comorbidities that worsen COVID-19 to severe levels and even lead to mortality. Treatment for COVID-19 patients associated with diabetes is a challenging task as multiple implications need to be managed. Adequate glycaemic control is another challenge in addition to the goal of reducing the severity of coronavirus load. It needs an extensive team effort to manage the complications in COVID-19 patients with diabetes (Apicella et al., 2017) .

The coronavirus on binding to the ACE2 receptors, especially on pancreatic beta-cells leads to acute loss of insulin secretory capacity in addition to cytokine storm which may lead to rapid metabolic deterioration. This lead to development of diabetic ketoacidosis or hyperglycaemic hyperosmolar syndrome (Hamming et al., 2004) .

On 26 If the COVID-19 patient is proposed to be on steroids treatment of any drugs with potential effect on glycaemic or else the severity of COVID-19 is increasing which may lead to stress glycaemia, then there should be a repeated monitoring of blood glucose levels. At any point of testing if the blood glucose level is 250 mg/dL, urine/blood ketone levels are to be tested and if found positive, then an endocrinologist need to be consulted immediately. At any point, if the blood glucose level of pre-meal is 300 mg/dL and/or post-meal is 400 J o u r n a l P r e -p r o o f 17 mg/dL, then an endocrinologist needs to be consulted immediately irrespective of ketone levels in order to initiate the insulin infusion. In the follow up testing on later days, fasting plasma glucose 126 mg/dL and/or HbA1c 6.5% are considered to be as diabetic mellitus positive.

In case the patient has no earlier diabetes,history but found to be diabetic during these tests with pre-meal blood glucose value 150-180 mg/dL and/or post-meal blood glucose value 200-250 mg/dL, then an endocrinologist needs to be consulted for initiating the oral antidiabetic drug treatment. In emergency cases to avoid delay in treatment, metformin and gliptin are advised. In case of excess values, insulin infusion can be initiated as advised by an endocrinologist.

Earlier reports reveal that administration of chloroquine or hydroxychloroquine may lead to hypoglycaemia especially in patients taking insulin or sulfonylureas, because of their effect on insulin secretion and degradation (Ünübol et al., 2011) . Also, antiviral drugs proposed for COVID-19 like lopinavir and ritonavir are known to cause hyperglycaemia and cause imbalance in the glycaemic control (Paengsai et al., 2019) . These antiviral agents can also cause hepatic and muscular toxicity when used along with statins in patients with fatty liver disease (Bruno et al., 2006) . Pharmacokinetic interactions are noticeable with antivirals against anti-diabetic drugs (Liverpool COVID-19 Interactions, 2020) . Use of glucocorticoids in COVID-19 patients with severe ARDS can worsen insulin resistance, glycaemic control, causing sever hyperglycaemia and sustained gluconeogenesis. This might be due to reduced insulin sensitivity and insulin secretion exerted by glucocorticoids and also by interfering with GLP-1 effects along with enhanced production of glucagon.

Hypertension is another most frequent comorbidity observed in COVID-19 patients(J. . Use of ACE inhibitors or ARBs in COVID-19 patients with hypertension has shown a lower rate of severe disease and a lower inflammatory response . ACE inhibitors are found to be unlikely to account for the connection of hypertension with COVID-19 (Reynolds et al., 2020 

Obesity associated COVID-19 lead to severe illness and death (Cariou et al., 2020; Shi et al., 2020) .Possible proposed mechanisms include detrimental restrictive ventilatory effect of abdominal fat, impaired lung perfusion due to intravascular disseminated coagulation, deep venous thrombosis, immune dysregulation, and chronic inflammation causing organ failure in severe COVID-19 cases (Connors & Levy, 2020; Sattar et al., 2020; Simonnet et al., 2020; Wichmann et al., 2020) .Low-molecular weight heparin was reported to reduce mortality rate in such COVID-19 associated obesity cases (Tang, Bai, et al., 2020) .

There is an increased risk of severity in COVID-19 patients with a BMI of >25 kg/m 2 and fatty liver disease than in patients without obesity .Obese patients due to physical inactivity, insulin resistance and gut dysbiosis, may result in inflammatory response to infection with COVID-19.Obese individuals suffer with chronic inflammation particularly elevated levels of IL-6 might be get beneficial results with the use of tocilizumab.

It can reduce the fever and oxygen requirement, however it may not be beneficial with acute therapy(X. . Horby et al. reported that dexamethasone use in obese patients with severe COVID-19 can reduce mortality rate by 8-26% (Horby et al., 2020) . Limited information is available for the use of other treatment options like statins, nonsteroidal antiinflammatory drugs and ARBs for obese patients with COVID-19 (Popkin et al., 2020) .

COVID-19 patients association with cardiovascular disease are also more prevailing ACE inhibitors and ARBs are not known to affect the morbidity and mortality of COVID-19 patients with cardiovascular disease.

High levels of c-reactive protein, ferritin, procalcitonin, neutrophil-to-lymphocyte ratio, inflammatory cytokines and chemokines are associated with both COVID-19 severity and mortality (Henry et al., 2020; Petrilli et al., 2020; Zhou et al., 2020) . COVID-19 is also associated with increased coagulation activity .

Pulmonary intravascular coagulation has been reported in COVID-19 patients (McGonagle et al., 2020) .

Vaccines are said to the most successful approach in preventing several infectious diseases in view of the fact that they are more effective than the treatment and can trim down the morbidity and mortality rate devoid of long-lasting effects (André, 2001; J o u r n a l P r e -p r o o f 20 2019). Since two decades, three corona viruses namely SARS-CoV, MERS-CoV, and SARS-CoV-2, were emerged throughout the world, creating significant threat to global health (Guarner, 2020) . Scientific experts feel that the pandemic of SARS-CoV-2 might be curtailed only by vaccination. Historically, there have been several difficulties faced by researchers in developing the vaccine for coronavirus. Coronavirus vaccines are not proven as effective in preventing the acquisition of disease, besides they found to be immunogenic in animal models (Koirala et al., 2020) . There is a concern that, vaccination may not induce lifelong immunity as with the natural infection and re-infection may be observed. Disappointedly, vaccines for SARS-CoV and MERS-CoV raised some safety concern related to Th2 mediated immunopathology in animal studies (Edridge et al., 2020; Roper & Rehm, 2009 ).

Coronaviruses consists of a helical nucleocapsid (N) covering single strand RNA genome and outer envelope having spike proteins (S), matrix proteins (M) and envelope protein (E) (Boopathi et al., 2020) . The S protein contains receptor binding domain (RBD), which is responsible for binding of ACE2 receptor and entry into the cell. Among all structural proteins, S protein was the major target antigen in vaccine development, as it found to elicit neutralising antibody (Buchholz et al., 2004; Walls et al., 2020) .

In current pandemic emergency of COVID-19, to contest this threatful condition, the world is truly required the potential vaccine. Vaccines approved for human use are generally Just weeks after the identification of SARS-CoV-2 genetic sequence, Moderna

Company together with NIAID, BARDA, made an announcement that mRNA-1273 (company's experimental COVID-19 vaccine) is all set for human trails (Zhai et al., 2020) .

This vaccine is one of the most hopeful and a notable fast vaccine development cycle was observed thereafter. 

Moderna applied lipid nanocarrier technology for mRNA-1273 to deliver the mRNA into the host cell unlike the conventional vaccination approach i.e., using of weakened strain of the virus to obtain SARS-CoV-2 specific antibodies and effective immune responses.

mRNA vaccine was proven to be superior in contrast to other conventional vaccines, as it possess high potency, safety and short production cycle (Ahn et al., 2020; Moderna, 2020 Phase 1 each formulation was received by 9 volunteers and in phase 2, 20 volunteers received the rAd26-S and rAd5-S (Logunov et al., 2020) . The primary objective of the study was to determine the safety and antigen specific humoral immunity and secondary outcome was to measure the antigen-specific cellular immunity and change in neutralising antibodies. As per their findings both the vaccine formulations were safe, well tolerated and shown only very common side effects. In phase 2, 85% of participants had detectable antibodies at 14 days after the priming dose, rising to 100% by day 21, with substantial titre rises after the boosting dose. All the participants who were treated with the formulations were produced both humoral and cell mediated immunity. Based on these findings Russian government and regulatory agencies has given approval for this vaccine to release into the Russian market for the common public.

However, scientific fraternity and regulatory agencies concerns that without the results of phase 3 study the approval is premature. Also, few scientists are stating that data on immune response alone would not generally be an adequate basis for approving a vaccine and "Immune response might not be directly proportional to the degree of protection.

Vaccine development is an organized, tedious, and long-run process, which usually takes around 10 years for the successful development. Nevertheless, researches and the developers are facing numerous challenges in diverse fronts, like regulatory constraints, time J o u r n a l P r e -p r o o f 29 and worsening of disease, scale up as per the demand etc., that seems to be difficult to meet (Lv et al., 2020) . never approve a vaccine that has not established its safety and effectiveness, amid concern in the hurry to develop the COVID-19 vaccine. Safety, efficacy, and potential adverse effects of currently used COVID-19 vaccines were summarized in Table 4 . are on basis of corona treatment, which is high frequency discharge that can augment the adhesion of plastic surfaces. Subsequently, we filtered these patents as they were out of the present scope of study and thus, selected 35 patents, which were having the application with respect to the COVID-19. Furthermore, we removed the patents which were not filed in English languages and duplicate patents. The short-listed patents are described in the Table   5 , (Patent analysis (COVID-19) , 2020)which contains basic details like, Jurisdiction (country of protection), Classification, Publication number, Title, Applicants and Inventors.Of all these, majority of the patents (14) were filed from United Kingdom (UK) Jurisdiction.

Country wise sharing of these patents were depicted in Fig. 5 . zinc (500mg Daily) and aspirin (100mg Daily), for 12 weeks can acts as a prophylaxis in preventing COVID-19 infections.

Disinfectant Bomb, was invented to disinfectant commercial areas and also helps in slow release spray for homes, offices and all modes of transports. Similar invention was developed to decontaminate the air using soap bubbles, comprising a solvent, surfactant (sodium laury/laureth sulphate) and evaporation suppressant (glycerol/polyethylene glycol).

Moreover, the process can be handled by connecting to wired or wireless devices to deliver or cease the production of soap bubbles.In another invention, apparatus and systems for cleaning of surfaces especially in an enclosable environment was described. The device or container spells out an air borne spray, spreads throughout the closed area and contact with the surfaces to be sterilized. The enclosableenvironment is maintained closed for an effective disinfection.

Majority of the researchers were focused not only on the treatment strategies and but also on diagnostic and disinfection devices, as evident from the above patent data. As the efficient diagnostic system helps for quick detection and isolation of COVID-19 effected patents, accordingly, mitigate the spread of the disease. Additionally, these tests can help to improve the understanding the virus spread and effectiveness of control measures. Health authorities throughout the world, are struggling to limit transmission of coronavirus. Disinfection is one of the suitable approaches. Disinfection will not reduce the spread of COVID-19, but also plays a significant role in flattening of the curve. Several inventors were filed the patents on all these strategies. Application of all these principles or methods can be effectively prevents/manage the current pandemic.

J o u r n a l P r e -p r o o f SARS-CoV-2, right from its onset, has shown multiple new variants of concern that made the therapeutic approach more complicated. Even the vaccine efficiency is encountered as a challenge with the changing variant of concerns. Due to the shared mutations in spike proteins mostly on S1 unit, there is a higher transmissibility rate and alter the viral virulence and clinical outcome. Even the mutations in non-structural proteins also became a challenge for researchers towards their vaccine development or therapeutic strategies. Several variants like alpha, beta, gamma, and delta are becoming complicated towards the management of patients. Hence, a combination of therapeutic strategies against viral cycle as well as immune host responses are in current trends (Khateeb et al., 2021) .

COVID-19 cases are rising day by day due to release of lockdown and community spread. Cumulative death factor is increasing across the globe. Several scientists are working for development of diagnostics, vaccines, drugs and struggling to understand the disease conditions. Comorbid diseases are noted as more favourable conditions for easy spread and severity of coronavirus infection. Throughout the world, so many countries are involved in the drug discovery and development either as industries, academia, research institutes, or collaborations. Till date, no vaccine or drug has been discovered or developed. Drug repurposing is the only symptomatic remedy as of now with emergency use authorizations of some existing drugs. The present review helps researchers or individuals or health workers to understand and know about the severity of disease, vaccine development status, patents filing and clinical trials progress, and available inline treatment strategies.

The authors declare no conflicts of interest.

The review did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. 

Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19)

Medics check on people with COVID-19 in Jinyintan Hospital

The future of vaccines, immunisation concepts and practice

Review COVID-19 in people with diabetes: understanding the reasons for worse outcomes

Myocardial injury and COVID-19: Possible mechanisms

Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-ofthe-Art Review

Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment

antiretroviral therapy with protease inhibitors: A review

Contributions of the structural proteins of severe respiratory syndrome coronavirus to protective immunity

The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial

The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

Celularity Announces FDA Clearance of IND Application for CYNK-001 in Coronavirus, First in Cellular Therapy

Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature

The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes

Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: A rescue trial in Beijing

Treatment of severe acute respiratory syndrome with glucosteroids: The Guangzhou experience

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Chinese Clinical Trial Register (ChiCTR) -The world health organization international organization registered platform

Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings

COVID-19 and its implications for thrombosis and anticoagulation

COVID-19 related analytics, graphs, and charts | Corona Tracker

Update: FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19 | FDA

Origin and evolution of pathogenic coronaviruses

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic. Diabetes and Metabolic Syndrome

Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment

Use of reninangiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study

Favipiravir as a potential countermeasure against neglected and emerging RNA viruses

Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus

Epidemiology of Cardiovascular Disease in China and Opportunities for Improvement: JACC International

Human coronavirus reinfection dynamics: lessons for SARS-CoV-2 Authors

Prevalence and impact of diabetes among people infected with SARS-CoV-2

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial

COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications

Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

& Ministry of Health & Family Welfare. (n.d.). Clinical Guidance on Diabetes Management at COVID-19 Patient Management Facility

The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review

Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection? Archives of

Evidence that vitamin d supplementation could reduce risk of influenza and covid-19 infections and deaths

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Comorbidity and its impact on 1,590 patients with Covid-19 in China: A nationwide analysis

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Clinical Characteristics of Coronavirus Disease 2019 in China

Three emerging coronaviruses in two decades: The story of SARS, MERS, and now COVID-19

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis

Novel Coronavirus in the United States

Dexamethasone for COVID-19-Preliminary Report Effect of Dexamethasone in Hospitalized Patients with COVID-19-Preliminary Report RECOVERY Collaborative Group

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

The economic and social burden of the

Ebola outbreak in West Africa

Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease 49

Transplantation of ACE2-Mesenchymal stem cells improves the outcome of patients with covid-19 pneumonia

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis. In Progress in Cardiovascular Diseases

The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Springer Nature

COVID-19: Progress in diagnostics, therapy and vaccination

Safety and immunogenicity of an rAd26 and rAd5 vector-based -boost COVID-19 vaccine in two formulations: two open, nonrandomised phase 1/2 studies from Russia

COVID-19 vaccines: Knowing the unknown

Ongoing Clinical Trials for the Management of the COVID-19 Pandemic

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia

COVID-19: consider cytokine storm syndromes and immunosuppression

Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives

Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Drug repurposing for viral infectious diseases: How far are we?

Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus | Moderna

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding

Recommended First-Line Antiretroviral Therapy Regimens and Risk of Diabetes Mellitus in HIV-Infected Adults in Resource-Limited Settings

The Lens -Free & Open Patent and Scholarly Search

Coronavirus Infections-More Than Just the Common Cold

Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease

Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships

Drug repurposing: Progress, challenges and recommendations

Renin-angiotensinaldosterone system inhibitors and risk of covid-19

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Convalescent Plasma to Treat COVID-19: Possibilities and Challenges

Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome

SARS vaccines: Where are we?

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized

Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Virology, pathogenesis, diagnosis and in-line treatment of COVID-19

Comorbidity and its Impact on Patients with COVID-19

Outcomes in Patients with Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? Diabetes Care

Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms

Use of chloroquine in viral diseases. The Lancet Infectious Diseases

Effects of chloroquine on viral infections: An old drug against today's diseases?

New insights into the antiviral effects of chloroquine

ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients with Diabetes in Wuhan, China: A Two-Center

The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication

High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation

Epidemiology, genetic recombination, and pathogenesis of coronaviruses

Cardiovascular manifestation and treatment in COVID-19

Anticoagulant treatment is of Thrombosis and Haemostasis

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis

Veklury (remdesivir) EUA Letter of Authorization

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Springer Nature

Remdesivir in adults with severe COVID-19: a randomised, doubleblind, placebo-controlled, multicentre trial. The Lancet

A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia

Springer Nature

Status of hypertension in China: Results from the China hypertension survey

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Coronavirus pathogenesis

After Ebola in West Africa -Unpredictable risks, preventable epidemics

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19

A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly

Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease

Characteristics of and Important Lessons from the

COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention

Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment

Effective treatment of severe COVID-19 patients with tocilizumab

Prevalence and control of diabetes in Chinese adults

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Healthy 2 Adults Aged 18-59 years: Report of the Randomized, Double-blind, and

Antimalaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model

Clinical characteristics and outcomes of patients with severe covid-19 with diabetes

Corticosteroid administration for viral pneumonia: COVID-19 and beyond

Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

The epidemiology, diagnosis and treatment of COVID-19

Advances in mRNA vaccines for infectious diseases

Current status of potential therapeutic candidates for the COVID-19 crisis

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Association of diabetes mellitus with disease severity and prognosis in COVID-19: A retrospective cohort study

Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease

Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in

China: a retrospective cohort study

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

A novel coronavirus from patients with pneumonia in China

 Reporting patents related information on COVID related aspects and till date, NO comprehensive review exists or has been published on it  This manuscript has special focus on Treatment strategies for COVID 19 with Comorbidities  Related Status of clinical trials of inline treatment approaches information was also added.  The current review submission is aesthetic with bright graphical abstract, good figures, tables, and info graphics.

☐The authors declare that they have no known competing financial interestsor personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Declared for the foresaid.J o u r n a l P r e -p r o o f